Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00081731 |
This study will compare medical therapy plus stenting of hemodynamically significant renal artery stenoses versus medical therapy alone in patients with systolic hypertension and renal artery stenosis.
Condition | Intervention | Phase |
---|---|---|
Atherosclerosis Cardiovascular Diseases Hypertension, Renovascular Renal Artery Obstruction |
Drug: Atacand Procedure: Angioplasty plus stenting |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment |
Official Title: | Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) |
Estimated Enrollment: | 1080 |
Study Start Date: | April 2004 |
Estimated Study Completion Date: | March 2010 |
Estimated Primary Completion Date: | January 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Optimal Medical Therapy: Active Comparator
Optimal anti-hypertensive therapy
|
Drug: Atacand
Atacand and caduet or optimal medical therapy for hypertension
|
Stenting: Experimental
Stent procedure plus optimal anti-hypertensive therapy
|
Procedure: Angioplasty plus stenting
Angioplasty plus stenting of the renal artery
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
One or more severe renal artery stenoses by any of the following pathways:
EXCLUSION CRITERIA:
United States, Ohio | |
University of Toledo | Recruiting |
Toledo, Ohio, United States, 43614 | |
Contact: Holly Burtch, RN 419-383-6289 holly.burtch@utoledo.edu | |
Contact: Christopher Cooper, M.D. | |
Principal Investigator: Christopher J. Cooper, MD |
Principal Investigator: | David Cohen, MD | Mid-America Heart Institute, St. Luke's Hospital, Kansas City, MO |
Principal Investigator: | Christopher J. Cooper, MD | University of Toledo |
Principal Investigator: | Donald Cutlip, MD | Beth Israel Deaconess Medcial Center |
Principal Investigator: | Alan Matsumoto, MD | University of Virginia School of Medicine |
Principal Investigator: | Michael Steffes, MD | University of Minnesota |
Responsible Party: | University of Toledo ( Christopher Cooper, MD ) |
Study ID Numbers: | 161, U01 HL71556 |
Study First Received: | April 19, 2004 |
Last Updated: | April 10, 2009 |
ClinicalTrials.gov Identifier: | NCT00081731 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Atherosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Agents Renal Artery Obstruction Arteriosclerosis Angiotensin II Antihypertensive Agents |
Hypertension, Renovascular Angiotensin II Type 1 Receptor Blockers Hypertension, Renal Candesartan cilexetil Urologic Diseases Candesartan Kidney Diseases Hypertension |
Atherosclerosis Arterial Occlusive Diseases Molecular Mechanisms of Pharmacological Action Vascular Diseases Cardiovascular Agents Renal Artery Obstruction Arteriosclerosis Antihypertensive Agents Pharmacologic Actions |
Hypertension, Renovascular Angiotensin II Type 1 Receptor Blockers Hypertension, Renal Candesartan cilexetil Urologic Diseases Therapeutic Uses Cardiovascular Diseases Kidney Diseases Hypertension |